Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial - Seferovic, Jelena P; Claggett, Brian; Seidelmann, Sara B; Seely, Ellen W; Packer, Milton; Zile, Michael R; Rouleau, Jean L; Swedberg, Karl; Lefkowitz, Martin; Shi, Victor C; Desai, Akshay S; McMurray, John J V; et al. (The lancet. Diabetes & endocrinology, 2017)
Keywords: Aged; Aminobutyrates - pharmacology; Aminobutyrates - therapeutic use; Angiotensin II Type 1 Receptor Blockers - pharmacology; Angiotensin II Type 1 Receptor Blockers - therapeutic use; Angiotensin-Converting Enzyme Inhibitors - pharmacology; Angiotensin-Converting Enzyme Inhibitors - therapeutic use; Blood Glucose - drug effects; Cardiology and Cardiovascular Disease; Diabetes Mellitus, Type 2 - complications; Drug Combinations; Enalapril - pharmacology; Enalapril - therapeutic use; Endocrinology & Metabolism; Female; Heart Failure - complications; Heart Failure - drug therapy; Humans; Kardiologi och kardiovaskulära sjukdomar; Male; Middle Aged; Other; Tetrazoles - pharmacology; Tetrazoles - therapeutic use; Valsartan - pharmacology; Valsartan - therapeutic use